CARDIOVASCULAR: Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results

Audio Journal of Cardiovascular Medicine, November 6th, 2007 Reporting from: American Heart Association Scientific Sessions, 4-7 November, 2007, Orlando, Florida Torcetrapib in Patients at High Risk for Coronary Events: ILLUMINATE Trial Latest Results PHILIP BARTER, Heart Research Institute, Sydney, Australia COMMENT: GORDON TOMASELLI, Johns Hopkins University, Baltmimore REFERENCE: Late Breaking Clinical Trials Session 2 A randomized double-blind study involving over 15,000 patients at high cardiovascular risk which looked at the new agent torcetrapib (an inhibitor of cholesteryl ester transfer protein, CETP) resulted in higher mortality in the experimental arm. The study compared torcetrapib plus atorvastatin with atorvatstin alone. Inhibition of CETP increases HDL levels and reduces LDL levels and should combat atherosclerosis. Sarah Maxwell spoke with Philip Barter who presented data on the ILLUMINATE trial at the American Heart Association meeting in Orlando.